We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
+2.79%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$720M
AUM Growth
-$49.3M
(-6.4%)
Cap. Flow
-$18.3M
Cap. Flow
% of AUM
-2.54%
Top 10 Holdings %
Top 10 Hldgs %
45.97%
Holding
78
New
15
Increased
29
Reduced
15
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ELGX
Endologix Inc
ELGX
|
+$16.8M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$13.2M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$11.5M |
| 4 |
SI-BONE Inc
SIBN
|
+$11.2M |
| 5 |
Codexis
CDXS
|
+$9.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$28.3M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$20.1M |
| 3 |
Harvard Bioscience
HBIO
|
+$19M |
| 4 |
Omnicell
OMCL
|
+$15.5M |
| 5 |
DVAX
Dynavax Technologies
DVAX
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.38% |
| 2 | Communication Services | 5.9% |
| 3 | Miscellaneous | 3.85% |
| 4 | Financials | 0.98% |
| 5 | Energy | 0.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $56.2M | 7.8% |
1,212,545
-1,009,176
| -45% | -$28.3M |
|
|
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $43.2M | 6% |
3,140,347
+396,868
| +14% | +$6.07M |
|
|
MODN
3
DELISTED
MODEL N, INC.
MODN
| $42.5M | 5.9% |
2,178,520
+2,926
| +0.1% | +$53.9K |
|
4
AtriCure
ATRC
$2.86B
| $33.2M | 4.61% |
1,111,740
+197,433
| +22% | +$5.76M |
|
5
NeoGenomics
NEO
$2.43B
| $29.1M | 4.04% |
1,325,582
-279,029
| -17% | -$6.12M |
|
|
6
Omnicell
OMCL
$1.49B
| $28.5M | 3.96% |
331,462
-190,587
| -37% | -$15.5M |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $27M | 3.75% |
537,999
+98,364
| +22% | +$4.79M |
|
8
Nektar Therapeutics
NKTR
$2.28B
| $25.4M | 3.53% |
47,585
-3,309
| -7% | -$1.66M |
|
|
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $23.9M | 3.31% |
1,800,997
+762
| +0% | +$10.7K |
|
|
10
Codexis
CDXS
$153M
| $22.2M | 3.08% |
1,205,523
+481,763
| +67% | +$9.29M |
|
|
11
Ionis Pharmaceuticals
IONS
$7.85B
| $21M | 2.92% |
327,132
-284,030
| -46% | -$20.1M |
|
12
Xencor
XNCR
$1.77B
| $20.4M | 2.84% |
499,344
-11,984
| -2% | -$394K |
|
13
Heron Therapeutics
HRTX
$59.6M
| $20.4M | 2.84% |
1,098,723
-14,243
| -1% | -$285K |
|
14
Halozyme
HALO
$12.1B
| $18.3M | 2.55% |
1,067,813
-403,685
| -27% | -$6.51M |
|
|
ELGX
15
DELISTED
Endologix Inc
ELGX
| $17.8M | 2.48% |
+2,462,448
| New | +$16.8M |
|
|
IMMU
16
DELISTED
Immunomedics Inc
IMMU
| $17M | 2.36% |
1,223,483
-181,230
| -13% | -$2.73M |
|
17
Veracyte
VCYT
$3.23B
| $16.8M | 2.33% |
589,099
-183,480
| -24% | -$4.58M |
|
|
XENT
18
DELISTED
Intersect ENT, Inc
XENT
| $15.2M | 2.11% |
668,893
-51,347
| -7% | -$1.38M |
|
19
Viatris
VTRS
$19.1B
| $14.2M | 1.97% |
743,784
+417,879
| +128% | +$9.24M |
|
|
AERI
20
DELISTED
Aerie Pharmaceuticals
AERI
| $14.1M | 1.96% |
478,174
+4,108
| +0.9% | +$158K |
|
|
21
SI-BONE Inc
SIBN
$831M
| $13.2M | 1.84% |
+651,319
| New | +$11.2M |
|
|
22
Agios Pharmaceuticals
AGIO
$1.96B
| $12.4M | 1.72% |
+247,897
| New | +$13.2M |
|
|
23
Ultragenyx Pharmaceutical
RARE
$1.29B
| $11.4M | 1.59% |
+180,017
| New | +$11.5M |
|
|
VAPO
24
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $11.4M | 1.59% |
62,121
+12,247
| +25% | +$1.81M |
|
25
Ligand Pharmaceuticals
LGND
$5.52B
| $11.3M | 1.56% |
158,134
-52,755
| -25% | -$3.89M |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q2 2019 Portfolio in Review
As of Q2 2019, First Light Asset Management held 78 positions worth $720M, down 6.4% from $770M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
First Light Asset Management's Q2 2019 filing shows 15 new, 29 increased, 15 reduced and 5 closed positions. Its largest new stake was Endologix Inc: 2,462,448 shares worth $17.8M. The largest sale was Array Biopharma Inc, an estimated $28.3M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 91% a quarter earlier, followed by Communication Services and Miscellaneous.
- First Light Asset Management's largest Q2 2019 buy was Endologix Inc: 2,462,448 shares worth $17.8M.
- First Light Asset Management added most to Codexis in Q2 2019, an estimated $9.29M increase.
- First Light Asset Management's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $28.3M.
- First Light Asset Management fully exited Dynavax Technologies in Q2 2019, selling an estimated $12.5M.
- First Light Asset Management's ten largest holdings make up 46% of its $720M portfolio in Q2 2019.
- First Light Asset Management opened 15 new positions and closed 5 in Q2 2019.
- First Light Asset Management's portfolio value fell 6.4% quarter-over-quarter to $720M.
Based on First Light Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.